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A B S T R A C T
The four receptor tyrosine kinases (RTKs) within the family of Fibroblast Growth Factor Receptors
(FGFRs) are critical for normal development but also play an enormous role in oncogenesis. Mutations
and/or abnormal expression often lead to constitutive dimerization and kinase activation of FGFRs, and
represent the primary mechanism for aberrant signaling. Sequencing of human tumors has revealed a
plethora of somatic mutations in FGFRs that are frequently identical to germline mutations in
developmental syndromes, and has also identiﬁed novel FGFR fusion proteins arising from chromosomal
rearrangements that contribute to malignancy. This review details approximately 200 speciﬁc point
mutations in FGFRs and 40 different fusion proteins created by translocations involving FGFRs that have
been identiﬁed in human cancer. This review discusses the effects of these genetic alterations on
downstream signaling cascades, and the challenge of drug resistance in cancer treatment with
antagonists of FGFRs.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Cytokine & Growth Factor Reviews
jo ur n al ho mep ag e: www .e lsev ier . c om / loc ate /c yto g f r1. Overview of canonical FGFR signaling
Receptor tyrosine kinases (RTKs) represent important signal
transducers in the cell membrane and are comprised of nearly
twenty families of homologous proteins in humans, with almost 60
distinct members [1]. In the FGFR family, four homologous human
receptors have been identiﬁed: FGFR1, FGFR2, FGFR3 and FGFR4.
All of the FGFRs exhibit three extracellular immunoglobulin (Ig)-
like domains, a membrane-spanning segment and a split tyrosineAbbreviations: ARMS, alveolar rhabdomyosarcoma; BSS, Beare Stevenson cutis
gyrata syndrome; CFS, chromosomal fragile site; CC, coiled coil domain; EMS, 8p11
myeloproliferative syndrome (EMS); ERMS, embryonal rhabdomyosarcoma; FN,
ﬁbronectin domain; Ig, immunoglobulin-like domain; IMD, IRSp53/MIM domain;
ITD, internal tandem duplication; JM, juxtamembrane domain; LIsH, LIS1-
homologous domain; LZ, leucine zipper domain; KD, kinase domain; KI, kinase
insert domain; LADD, lacrimo auriculo dento digital syndrome; ORF, open reading
frame; RMS, rhabdomyosarcoma; SAM, sterile alpha motif; SADDAN, severe
achondroplasia with delayed development and acanthosis nigricans; SP, signal
peptide; SPFH, stomatin/prohibitin/ﬂotillin/HﬂK/C domain; TK domain, tyrosine
kinase domain; TD, thanatophoric dysplasia; TM, transmembrane domain; ZF, zinc
ﬁnger domain.
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4.0/).kinase domain. Fibroblast Growth Factors (FGFs), a large family of
related growth factors, act in concert with heparin sulfate
proteoglycans (HSPGs) as high-afﬁnity FGFR agonists [2,3]. The
splicing of FGFRs results in further distinction of ligand speciﬁcity
accompanied by altered biological properties, in which the most
studied splicing isoforms involve the third immunoglobulin-like
domain of the receptors [4]. For FGFR2 and FGFR3, the ﬁrst half of
third Ig domain consists of an invariant exon (IIIa), and splicing of
the second half of third Ig domain results in either IIIb isoform
(exons 7 and 8) or IIIc isoform (exons 7 and 9). Generally, the IIIb
isoforms of FGFRs are expressed in tissues of epithelial origin
whereas the IIIc isoforms are expressed in mesenchymal tissues
[5].
Binding of FGF/HSPG to FGFR induces the dimerization of
receptor monomers in the plasma membrane, followed by trans-
autophosphorylation of tyrosine residues located in the cyto-
plasmic kinase domain. This tyrosine phosphorylation triggers the
binding of Src homology (SH2) domain of phospholipase C gamma
(PLCg) to the receptor, resulting in the activation of PKC. Activation
also induces RAS–MAPK and PI3K–AKT signaling via FRS2 and
GRB2 adaptor proteins. Additional pathways activated by FGFRs
include Jun N-terminal kinase and JAK/STAT pathways. FGFR
signaling results in cellular proliferation and migration, anti-
apoptosis, angiogenesis and wound healing (Fig. 1) [6].e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. FGFR signaling pathways. FGF ligand binds to FGFR monomers, leading to the dimerization and subsequent tyrosine autophosphorylation of the receptor. This event
leads to activation of FGFRs and various downstream proteins, resulting in cellular proliferation, differentiation, survival, anti-apoptosis and angiogenesis.
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2.1. Nomenclature of mutations with respect to isoforms
The alternatively spliced isoforms of FGFR1, FGFR2 and FGFR3
result in considerable confusion in numbering speciﬁc mutations,
depending upon the convention employed by the original authors.
In Table 1, we have presented the residue numbers in FGFR1 for
both the aA1 and aB1 isoforms, in FGFR2 for the IIIb and IIIc
isoforms, in FGFR3 for the IIIb and IIIc isoforms, and FGFR4 for the
Uniprot P22455-1 and P22455-2 isoforms. Throughout this
manuscript, we will refer to the numbering for the isoforms
FGFR1 aA1, FGFR2 IIIb, FGFR3 IIIb, and full-length FGFR4 (Uniprot
P22455-1), although a speciﬁc mutation may have been described
initially in the other isoform. Rarely, a mutation may occur at a
residue that is not present in either of the most common isoforms;
in these unusual cases, this other isoform is identiﬁed in Table 1.
2.2. Cysteine mutations in the extracellular domain lead to aberrant
activation of FGFRs
Many mutations in the extracellular domains of FGFRs induce
tyrosine kinase activation by disulﬁde bond disruption. For
instance, each Ig domain of FGFR2 is stabilized by a disulﬁde
bond between pairs of cysteine residues: Cys62 and Cys107 in Ig-I,Cys179 and Cys231 in Ig-II, Cys278 and Cys340 in Ig-III [7].
Mutations in FGFR2 that perturb a disulﬁde bond in the
extracellular domain result in increased receptor activation, such
as the C278F mutation in Crouzon and Pfeiffer Syndromes, or the
mutation of C340 to S or Y in Crouzon Syndrome. These are
examples of craniosynostosis syndromes exhibiting premature
closure of cranial sutures, accompanied by defects in chondrocyte
signaling and brain development [8]. This same theme is
recapitulated in somatic mutations involved in human cancer as
exempliﬁed by the C278F mutation and the mutations C340F/R/S/
W/Y identiﬁed in spermatocytic seminoma [9]. Conceptually
similar mutations that remove a critical Cys residue also occur
in FGFR3 and FGFR4 (Table 1, Fig. 2).
Conversely, the addition of a single cysteine mutation creates an
unpaired cysteine that can participate in abnormal intermolecular
disulﬁde bond formation leading to receptor activation. One such
example is FGFR2 W290C, a mutation causing Pfeiffer Syndrome,
which has also been identiﬁed in lung squamous cell carcinoma
and spermatocytic seminoma (Table 1). A conceptually similar
mutation is that of FGFR2 S352C in Crouzon Syndrome [10,11], also
identiﬁed in spermatocytic seminoma. Other examples of FGFR2
mutations that introduce a new cysteine residue in the extracellu-
lar domain include R203C, Y281C, S320C, Y338C, and S373C, which
have been identiﬁed in various cancers including breast cancer,
endometrial carcinoma, lung squamous cell carcinoma and
Table 1
Mutations in FGFRs identiﬁed in diverse human cancers.
FGFR1
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue
in aA1
Residue
in aB1
Other
isoform
Breast cancer S125L S125L IgI–IgII [141]
Colorectal cancer P150S P150S bA1: P61S IgI–IgII [142]
A268S A268S IgII–IgIII [34]
S430F S428F A JM [142]
A431S A429S JM [143]
G610D G608D A KD2 [142]
Esophageal
adenocarcinoma
K598N K596N KD2 [144]
Gallbladder cancer S125L S125L IgI–IgII [107]
Gastric cancer A268S A268S IgII–IgIII [34]
Glioblastoma N546K N544K KD1 Analogous to FGFR2 N549K in Crouzon and Pfeiffer Syndromes; Analogous to
FGFR3 N540K in Hypochondroplasia
[145]
R576W R574W KD1 [145]
K656E K654E KD2 Analogous to FGFR2mutation K659E in Syndromic Craniosynostosis; Analogous to
FGFR3 mutation K650E in TDII
[65]
Head and neck
squamous cell
carcinoma
n/a n/a P11362-21
G33R
N-term [146]
E334Q E334Q IgIII [70]
Lung
adenocarcinoma
P252T P252T IgII–IgIII Mutation causes Pfeiffer Syndrome; Analogous to FGFR2 mutations at P253 in
Pfeiffer and Apert Syndromes; Analogous to FGFR3 mutation at P250 in Syndromic
Craniosynostosis
[141,147]
Lung large cell
carcinoma
V664L V662L KD2 [141]
Lung squamous
cell carcinoma
G70R G70R IgI [148]
T141R T141R IgI–IgII [148]
Melanoma P252S P252S IgII–IgIII Mutation causes Pfeiffer Syndrome; Analogous to FGFR2 mutations at P253 in
Pfeiffer and Apert Syndromes; Analogous to FGFR3 mutation at P250 in Syndromic
Craniosynostosis
[34,149]
Pilocytic
astrocytoma
N546K N544K KD1 Analogous to FGFR2 N549K in Crouzon and Pfeiffer Syndromes; Analogous to
FGFR3 N540K in Hypochondroplasia
[60]
K655I K653I KD2 [60]
K656D/E/
M/N
K654D/E/
M/N
KD2 Analogous to FGFR2mutation K659E in Syndromic Craniosynostosis; Analogous to
FGFR3mutations: K650E in TDII, K650M in SADDAN, K650N in Hypochondroplasia
[60]
T658P T656P KD2 [60]
Prostate cancer R78H R78H IgI [34]
Rosette forming
glioneuronal
tumor
N546K N544K KD1 Analogous to FGFR2 N549K in Crouzon and Pfeiffer Syndromes; Analogous to
FGFR3 N540K in Hypochondroplasia
[64]
K656E K654E KD2 Analogous to FGFR2mutation K659E in Syndromic Craniosynostosis; Analogous to
FGFR3 mutation K650E in TDII
[64]
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Table 1 (Continued )
FGFR1
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue
in aA1
Residue
in aB1
Other
isoform
Spermatocytic
seminoma
P252R/T P252R/T IgII–IgIII Mutation causes Pfeiffer Syndrome; Analogous to FGFR2 mutations at P253 in
Pfeiffer and Apert Syndromes; Analogous to FGFR3 mutation at P250 in Syndromic
Craniosynostosis
[9]
N330I N330I IgIII Mutation causes Osteoglophonic Dysplasia [9]
Y374C Y374C TM Mutation causes Osteoglophonic Dysplasia; Analogous to FGFR2 Y375C in Beare–
Stevenson Cutis Gyrata Syndrome; Analogous to FGFR3 Y373C in TDI
[9]
C381R C381R TM Mutation causes Osteoglophonic Dysplasia [9]
R576W R574W KD1 [9]
FGFR2
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue
in IIIb
Residue
in IIIc
Other
isoform
Adenoid cystic
carcinoma
Y376C Y375C TM Mutation causes Beare–Stevenson Cutis Gyrata Syndrome; Analogous to FGFR1
Y374C in Osteoglophonic Dysplasia; Analogous to FGFR3 Y373C in TDI
[150]
K642R K641R KD2 Mutation causes Pfeiffer Syndrome [150]
Bladder cancer M186T M186T P21802-20
M71T
IgII Mutation causes Apert Syndrome [34]
Breast cancer R203C R203C IgII [12,141]
N550K N549K KD1 Mutation causes Crouzon and Pfeiffer Syndromes; Analogous to FGFR3 N540K in
Hypochondroplasia
[92]
S588C S587C KI [92]
K660N K659N KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutation
K650N in Hypochondroplasia
[12]
Cervical squamous
cell carcinoma
A97T A97T IgI [23]
S252L S252L IgII–IgIII Mutation causes Apert Syndrome; Mutations in FGFR3 at S249 cause TDI [58]
P256S P256S IgII–IgIII [58]
K406E K405E JM [58]
M585V M584V KI [58]
Y589D Y588D KI [58]
K660M K659M KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutation
K650M in SADDAN
[23]
Colorectal cancer R203H R203H P21802-20
R88H
IgII [142]
R210Q R210Q P21802-20
R95Q
IgII [142]
D334N D336N P21802-20
D221N
IgIII [142]
Q361R n/a IgIII-TM [151]
L552I L551I KD1 [142]
P583L P582L KI [151]
R665W R664W KD2 [142]
E778K E777K C-term [142]
L.H
.
 G
a
llo
 et
 a
l.
 /
 C
y
to
k
in
e
 &
 G
ro
w
th
 Fa
cto
r
 R
ev
iew
s
 2
6
 (2
0
1
5
)
 4
2
5
–
4
4
9
4
2
8
Endometrial
carcinoma
D101Y D101Y IgI [23]
S252W S252W IgII–IgIII Mutation causes Apert Syndrome; FGFR3 mutation at S249 causes TDI [23,32,152]
P253R P253R IgII–IgIII Mutation causes Apert Syndrome; Analogous to FGFR1 mutations at P252 in
Pfeiffer Syndrome; Analogous to FGFR3mutation at P250 inMuenke Syndrome and
Nonsyndromic Craniosynostosis
[23,152]
K310R K310R IgIII [23,32]
n/a A314D IgIII Mutation causes Pfeiffer Syndrome and Unicoronal Non-Syndromic
Craniosynostosis
[23]
n/a A315T IgIII Mutation causes Crouzon Syndrome and Unicoronal Non-Syndromic
Craniosynostosis
[32]
S373C S372C IgIII–TM Mutation causes Beare–Stevenson Cutis Gyrata Syndrome [32,152]
Y376C Y375C TM Mutation causes Beare–Stevenson Cutis Gyrata Syndrome; Analogous to FGFR1
Y374C in Osteoglophonic Dysplasia; Analogous to FGFR3 Y373C in TDI
[32,152]
C383R C382R TM Analogous to FGFR1 C381R in Osteoglophonic Dysplasia [23,32,152]
A390T A389T TM [23]
M392R M391R TM [32,152]
V396D V395D TM [152]
L398M L397M TM [152]
I548D/V I547D/V KD1 [32,152]
N550H/K N549H/K KD1 Mutation causes Crouzon Syndrome; Analogous to FGFR3 N540K in
Hypochondroplasia
[23,32,152]
K660E/M/N K659E/M/N KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutations:
K650E in TDII, K650M in SADDAN, K650N in Hypochondroplasia
[23,32,152]
Esophageal
adenocarcinoma
C383R C382R TM Analogous to FGFR1 C381R in Osteoglophonic Dysplasia [144]
Gallbladder cancer S252W S252W IgII–IgIII Mutation causes Apert Syndrome; FGFR3 mutation at S249 causes TDI [107]
N550K N549K KD1 Mutation causes Crouzon and Pfeiffer Syndromes; Analogous to FGFR3 N540K in
Hypochondroplasia
[107]
Gastric cancer S267P S267P IgII–IgIII Mutation causes Crouzon Syndrome, Pfeiffer Syndrome, Apert Syndrome [153]
Glioblastoma Q212K Q212K IgII [65]
G463E G462E JM [151]
Head and neck
squamous cell
carcinoma
N550D/K N549D/K KD1 Mutation causes Crouzon and Pfeiffer Syndromes; Analogous to FGFR3 N540K in
Hypochondroplasia
[70]
Lung
adenocarcinoma
E116K E116K IgI–IgII [154]
P253L P253L IgII–IgIII Mutation causes Apert Syndrome; Analogous to FGFR1 mutations at P252 in
Pfeiffer Syndrome; Analogous to FGFR3mutation at P250 inMuenke Syndrome and
Nonsyndromic Craniosynostosis
[154]
I381V I380V TM [148]
K421I K420I JM [154]
D480N D479N JM [154]
H545Q H544Q KD1 [148]
G584V G583V KI [154]
I591M I590M KI [154]
Q621K Q620K KD2 [154]
R626T R625T p.R496T KD2 [141]
Lung squamous
cell carcinoma
D138N D138N IgI–IgII [154]
N211I N211I IgII [23]
D247Y D247Y IgII–IgIII [154]
D283N D283N IgIII [141,147]
W290C W290C IgIII Mutation causes Pfeiffer Syndrome [13,23,98,147,154]
G302W G302W IgIII [154]
S320C n/a IgIII [13,154]
C383R C382R TM Analogous to FGFR1 C381R in Osteoglophonic Dysplasia [154]
E471Q E470Q JM [13,98,154]
M538I M537I KD1 [154]
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Table 1 (Continued )
FGFR2
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue
in IIIb
Residue
in IIIc
Other
isoform
G584W G583W KI [98,154]
D603E D602E KD2 [154]
K660E/N K659E/N KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutations:
K650E in TDII, K650N in Hypochondroplasia
[13,98,154]
L773F L772F C-term [154]
T787K T786K C-term [13,98,154]
Lymphoma M186T M186T P21802-20
M71T
IgII Mutation causes Apert Syndrome [34]
Medulloblastoma K660E K659E KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutation
K650E in TDII
[155]
Melanoma S24F S24F N-term [75]
V77M V77M IgI [75]
H213Y H213Y IgII [75]
E219K E219K IgII [75]
G227E G227E IgII [75]
V248D V248D IgII–IgIII [75]
R251Q R251Q IgII–IgIII [75]
G271E G271E IgII–IgIII [75]
G305R G305R IgIII [75]
T371R T370R IgIII-TM [75]
E476K E475K JM [75]
D531N D530N KD1 [75]
E575K E574K KD1 [75]
E637K E636K KD2 [75]
M641I M640I KD2 [75]
I643V I642V KD2 [75]
A649T A648T KD2 Mutation causes Lacrimo-Auriculo-Dento-Digital Syndrome [75]
S689F S688F KD2 [75]
G702S G701S KD2 [75]
P709S P708S KD2 [75]
R760Q R759Q C-term [75]
L771V L770V C-term [75]
Oral squamous
cell carcinoma
P253R P253R IgII–IgIII Mutation causes Apert Syndrome; Analogous to FGFR1 mutations at P252 in
Pfeiffer Syndrome; Analogous to FGFR3mutation at P250 inMuenke Syndrome and
Nonsyndromic Craniosynostosis
[13]
V393A V392A TM [156]
Ovarian serous
carcinoma
G272V G272V IgII–IgIII [141]
Pilocytic astrocytoma K660E K659E KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutation
K650E in TDII
[60]
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Spermatocytic
seminoma
S252F/W S252F/W IgII–IgIII Mutation causes Apert Syndrome; Mutations in FGFR3 at S249 cause TDI [9]
P253R/S P253R/S IgII–IgIII Mutation causes Apert Syndrome; Analogous to FGFR1 mutations at P252 in
Pfeiffer Syndrome; Analogous to FGFR3mutation at P250 inMuenke Syndrome and
Nonsyndromic Craniosynostosis
[9]
S267P S267P IgII–IgIII Mutation causes Crouzon Syndrome [9]
F276V F276V IgII–IgIII Mutation causes Crouzon Syndrome [9]
C278F C278F IgIII Mutation causes Crouzon and Pfeiffer Syndromes [9]
Y281C Y281C IgIII Mutation causes Crouzon Syndrome [9]
Q289P Q289P IgIII Mutation causes Crouzon Syndrome [9]
W290C W290C IgIII Mutation causes Pfeiffer Syndrome [9]
n/a A315S IgIII Mutation causes Crouzon Syndrome and Unicoronal Non-Syndromic
Craniosynostosis
[9]
G336R G338R IgIII Mutation causes Crouzon Syndrome [9]
Y338C/H Y340C/H IgIII Mutation causes Crouzon and Pfeiffer Syndromes [9]
n/a T341P IgIII Mutation causes Pfeiffer Syndrome [9]
C340F/R/S/
W/Y
C342F/R/S/
W/Y
IgIII Mutation causes Crouzon and Pfeiffer Syndromes [9]
n/a A344G/P IgIII–TM Mutation causes Crouzon Syndrome [9]
n/a S347C IgIII–TM Mutation causes Crouzon Syndrome [9]
S352C S354C IgIII–TM Mutation causes Crouzon Syndrome [9]
Y376C Y375C TM Mutation causes Beare–Stevenson Cutis Gyrata Syndrome; Analogous to FGFR1
Y374C in Osteoglophonic Dysplasia; Analogous to FGFR3 Y373C in TDI
[9]
K527E K526E KD1 Mutation causes Crouzon Syndrome [9]
N550K N549K KD1 Mutation causes Crouzon and Pfeiffer Syndromes; Analogous to FGFR3 N540K in
Hypochondroplasia
[9]
K642R K641R KD2 Mutation causes Pfeiffer Syndrome [9]
K660E K659E KD2 Mutation causes Syndromic Craniosynostosis; Analogous to FGFR3 mutation
K650E in TDII
[9]
FGFR3
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue
in IIIb
Residue
in IIIc
Other
isoform
Bladder cancer E216K E216K IgII [157]
D222N D222N IgII [157]
G235D G235D IgII–IgIII [157]
R248C R248C IgII–IgIII Mutation causes TDI [49,53,101,
157–164]
S249C S249C IgII–IgIII Mutation causes TDI; Mutations in FGFR2 at S252 cause Apert Syndrome [49,53,101,
157–166]
P283S P283S IgIII [101]
V306I V306I IgIII [157]
n/a H349Y IgIII–TM [157]
G372C G370C IgIII–TM Mutation causes TDI [49,101,
157–163,166]
S373C S371C IgIII–TM Mutation causes TDI [101,158,164]
Y375C Y373C TM Mutation causes TDI; Analogous to FGFR1 Y374C in Osteoglophonic Dysplasia;
Analogous to FGFR2 Y375C in Beare–Stevenson Cutis Gyrata Syndrome
[49,53,101,
157–160,163,
164,166,167]
I378C I376C TM [164]
Y381C Y379C TM [163]
G382R G380R TM Mutation causes Achondroplasia [49,157,158,
161,164,165]
F386L F384L TM [164]
A393E A391E TM Mutation causes Crouzon Syndrome with Acanthosis Nigricans [158,159,161,
163,164,167]
N542S N540S KD1 Mutation causes Hypochondroplasia; Analogous to FGFR2 mutations at N549 in
Crouzon Syndrome
[165]
K652E/M/
Q/T
K650E/M/
Q/T
KD2 Mutation to E causes TDII; Mutation to M causes SADDAN; Mutation to Q/T causes
Hypochondroplasia
[101,141,
158–162,166]
L.H
.
 G
a
llo
 et
 a
l.
 /
 C
y
to
k
in
e
 &
 G
ro
w
th
 Fa
cto
r
 R
ev
iew
s
 2
6
 (2
0
1
5
)
 4
2
5
–
4
4
9
 
4
3
1
Table 1 (Continued )
FGFR3
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue
in IIIb
Residue
in IIIc
Other
isoform
Breast cancer n/a n/a P22607-4
P688S
KD2 [92]
Cervical cancer S249C S249C IgII–IgIII Mutation causes TDI; Mutations in FGFR2 at S252 cause Apert Syndrome [162]
Colorectal cancer C228R C228R IgII [141]
n/a E322K IgIII [153]
R401C R399C JM [142]
V679I V677I KD2 [142]
Esophageal
adenocarcinoma
n/a A341T IgIII–TM [144]
Gallbladder cancer R248C R248C IgII–IgIII Mutation causes TDI [107]
S249C S249C IgII–IgIII Mutation causes TDI; Mutations in FGFR2 at S252 cause Apert Syndrome [107]
G372C G370C IgIII–TM Mutation causes TDI [107]
Y375C Y373C TM Mutation causes TDI; Analogous to FGFR1 Y374C in Osteoglophonic Dysplasia;
Analogous to FGFR2 Y375C in Beare–Stevenson Cutis Gyrata Syndrome
[107]
G382R G380R TM Mutation causes Achondroplasia [107]
K652M K650M KD2 Mutation causes SADDAN [107]
G699C G697C KD2 [107]
Glioblastoma E468K E466K JM [168]
R605Q R603Q KD2 [169]
Head and neck
squamous cell
carcinoma
Q209H Q209H IgII [170]
S249C S249C IgII–IgIII Mutation causes TDI; Mutations in FGFR2 at S252 cause Apert Syndrome [70] [171]
F388L F386L TM [146]
K415N K413N JM [70]
K652N K650N KD2 Mutation causes Hypochondroplasia [171]
Lung
adenocarcinoma
T79S T79S IgI [141]
Lung
squamous cell
carcinoma
R248C/H R248C/H IgII–IgIII Mutation causes TDI [13,98,172]
S249C S249C IgII–IgIII Mutation causes TDI; Mutations in FGFR2 at S252 cause Apert Syndrome [13,98]
S435C S433C JM [13]
K717M K715M KD2 [13,98]
Mesothelioma D648Y D646Y KD2 [173]
Multiple myeloma G197S G197S IgII [174]
Y241C Y241C IgII–IgIII [175]
R248C R248C IgII–IgIII Mutation causes TDI [176,177]
Y375C Y373C TM Mutation causes TDI; Analogous to FGFR1 Y374C in Osteoglophonic Dysplasia;
Analogous to FGFR2 Y375C in Beare–Stevenson Cutis Gyrata Syndrome
[43,178]
G384D G382D TM [178]
F386L F384L TM [43,179]
S435C S433C JM [174]
K652E/M K650E/M KD2 Mutation to E causes TDII; Mutation to M causes SADDAN [43,174,178]
L796R L794R C-term [180]
P797A P795A C-term [180]
Oral squamous cell
carcinoma
G699C G697C KD2 [181]
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Seborrheic keratosis R248C R248C IgII–IgIII Mutation causes TDI [182]
S249C S249C IgII–IgIII Mutation causes TDI; Mutations in FGFR2 at S252 cause Apert Syndrome [182]
G372C G370C IgIII–TM Mutation causes TDI [182]
S373C S371C IgIII–TM Mutation causes TDI [182]
A393E A391E TM Mutation causes Crouzon Syndrome with Acanthosis Nigricans [182]
K652E/M K650E/M KD2 Mutation to E causes TDII; Mutation to M causes SADDAN [182]
Spermatocytic
seminoma
R248C R248C IgII–IgIII Mutation causes TDI [9]
S249C S249C IgII–IgIII Mutation causes TDI; FGFR2 S252F/W causes Apert Syndrome [9]
P250R P250R IgII–IgIII Mutation causes Muenke Syndrome and Nonsyndromic Craniosynostosis; FGFR1
mutation at P252 causes Pfeiffer Syndrome; FGFR2 mutation at P253 causes Apert
and Pfeiffer Syndromes
[9]
E370K E368K IgIII–TM [9]
G372C G370C IgIII–TM Mutation causes TDI [9]
S373C S371C IgIII–TM Mutation causes TDI [9]
Y375C Y373C TM Mutation causes TDI; Analogous to FGFR1 Y374C in Osteoglophonic Dysplasia;
Analogous to FGFR2 Y375C in Beare–Stevenson Cutis Gyrata Syndrome
[9]
G377C G375C TM Mutation causes Achondroplasia [9]
G382R G380R TM Mutation causes Achondroplasia [9]
A393E A391E TM Mutation causes Crouzon Syndrome with Acanthosis Nigricans [9]
N542K/S/T/
V
N540K/S/T/
V
KD1 Mutation causes Hypochondroplasia; Analogous to FGFR2 mutations at N549 in
Crouzon and Pfeiffer Syndromes
[9]
K652E/M/
N/Q/T
K650E/M/
N/Q/T
KD2 Mutation to E causes TDII; Mutation to M causes SADDAN; Mutation to N/Q/T
causes Hypochondroplasia
[9]
G699C G697C KD2 [9]
X809C/G/R/
T
X807C/G/R/
T
C-term Mutation causes TDI [9]
FGFR4
Disease Mutation/isoform Location in receptor Role in developmental syndromes Reference
Residue in
P22455-1
Residue in
P22455-2
Other
isoform
Breast cancer E326K E326K IgIII [92]
Y367C n/a TM Analogous to FGFR1 Y374C in Osteoglophonic Dysplasia; Analogous to FGFR2
Y375C in Beare–Stevenson Cutis Gyrata Syndrome; Analogous to FGFR3 Y373C in
TDI
[34]
A484T A444T KD1 [92]
V550M V510M KD1 [141]
Colorectal
cancer
P583Q P543Q KI [142]
A614S A574S KD2 [142]
Glioblastoma Q144E Q144E IgI–IgII [65]
R434Q R394Q JM [65]
Head and neck
squamous cell
carcinoma
D671N D631N KD2 [70]
Lung
adenocarcinoma
R183S R183S IgII [148]
S232I S232I IgII–IgIII [148]
R616G R576G KD2 [148]
E681K E641K KD2 [148,183]
P712T P672T KD2 [141,147]
A729G A689G KD2 [148]
Lung neuroendocrine
carcinoma
S772N S732N C-term [141]
Lung squamous cell
carcinoma
Q144E Q144E IgI–IgII [98]
R434Q R394Q JM [98]
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L.H. Gallo et al. / Cytokine & Growth Factor Reviews 26 (2015) 425–449434spermatocytic seminoma (Table 1, Fig. 2). Some of these
mutations have been shown to result in increased receptor
autophosphorylation and elevated phosphorylation of FRS2,
MAPK and STAT3 [12]. The FGFR2 W290C and S320C mutants
have been shown to contribute to tumor formation in xenograft
models, and such tumors were sensitive to a selective FGFR
inhibitor BJG398, which caused dramatic tumor shrinkage [12].
Overall, these gain-of-function mutations lead to constitutive
FGFR activation and drive cellular proliferation and tumor
progression. Note that in Fig. 2, all mutations such as W290C
that have been identiﬁed in human cancer and as developmental
syndromes are shown in red. Mutations identiﬁed only in human
cancer are shown in black.
Mutations that introduce a novel cysteine residue also occur in
FGFR3, such as R248C and S249C which, as congenital mutations,
cause Thanatophoric Dysplasia Type I (TDI), a severe achondro-
plasia typically causing neonatal lethality. As somatic mutations,
they have been identiﬁed in bladder cancer, cervical cancer,
gallbladder cancer, head and neck squamous cell carcinoma, lung
squamous cell carcinoma, multiple myeloma, sebborheic keratosis,
and spermatocytic seminoma (Table 1). These mutations are able
to induce colony formation in NIH3T3 anchorage-independent
assays, transform myeloid Ba/F3 cells to IL-3 independence [13]
and cause ligand-independent receptor activation [14]. Treating IL-
3-independent Ba/F3 cells expressing these FGFR mutants with the
multikinase inhibitor ponatinib (AP24534) inhibited proliferation
[13].
2.3. Non-cysteine mutations in the extracellular domain lead to
aberrant activation
Non-cysteine mutations in the extracellular domain are also
able to activate FGFRs, such as P252R/S/T mutations in FGFR1 in
melanoma, lung adenocarcinoma and spermatocytic seminoma
(Table 1). Autosomal dominant mutations at this codon lead to
Pfeiffer Syndrome [15]. This residue is located in the IgII–IgIII
linker region and contributes to increased receptor activation by
decreasing the dissociation rate of the receptor and the FGF ligand
[16]. Mutations in the analogous FGFR2 residue, P253R/S, are
associated with Apert Syndrome [17,18] and have been frequently
identiﬁed in cancers, including endometrial carcinoma, lung
adenocarcinoma, oral squamous cell carcinoma and spermatocytic
seminoma (Table 1). Cells expressing FGFR2 P253R exhibit
increased FRS2 phosphorylation and increased FGF2- and FGF9-
induced activation of MAPK signaling [19]. A patient with oral
squamous cell carcinoma expressing FGFR2 P253R responded to
the multikinase inhibitor pazopanib (GW786034B), which effec-
tively reversed cellular transformation and contributed to tumor
shrinkage [13].
Another well-studied non-cysteine substitution is S252W in
FGFR2, which occurs in approximately 67% of patients with Apert
Syndrome, a developmental syndrome characterized by cranio-
synostosis and syndactyly [20,21]. The pathophysiological effect of
this mutation comes from the higher afﬁnity of FGFR2 for a greater
repertoire of FGF ligands due to the formation of a hydrophobic
patch that stabilizes the ligand-receptor interaction [16]. This
mutation leads to aberrant activation of MAPK signaling and
interferes with proper endochondral bone development [22].
Mutations at this position, either S252W, S252F, or S252L, have
been identiﬁed in cervical squamous cell carcinoma, endometrial
carcinoma, gallbladder cancer and spermatocytic seminoma
(Table 1). FGFR2 S252W leads to colony formation and anchor-
age-independent proliferation of endometrial carcinoma cells,
whereas treatment with FGFR inhibitor PD173074 results in
decreased FRS2 phosphorylation, colony formation and tumor cell
proliferation [23].
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Fig. 2. FGFR mutations identiﬁed in human cancer. Mutations present in both developmental syndromes and cancers are highlighted in red. Mutations present only in cancer
are shown in black. The residue numbers are based on the following isoforms according to Table 1: aA1 for FGFR1, IIIb for FGFR2, IIIb for FGFR3, and full-length form FGFR4
(Uniprot P22455-1).
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especially numerous for FGFR2 (Fig. 2), have been overwhelmingly
detected in both developmental syndromes and cancers. These
mutations lead to aberrant receptor signaling either by abnormal
disulﬁde bond formation and receptor dimerization or by
increasing the afﬁnity of the receptor for an expanded repertoire
of FGF ligands.
2.4. Activating mutations in the transmembrane domain of FGFRs
Biochemical studies suggest that activating mutations adja-
cent to or within the transmembrane domain of RTKs induce a
rotation in the dimer interface of receptor monomers, contribut-
ing to increased receptor activation [24]. Recently, the juxta-
membrane domain has been shown to synergize with thetransmembrane domain to stabilize the unliganded FGFR3 dimer
[25].
The introduction of an abnormal Cys residue in the transmem-
brane domain of FGFRs represents one category of activating
mutation. For instance, the Y376C mutation in the transmembrane
domain of FGFR2 has been identiﬁed in adenoid cystic carcinoma,
endometrial carcinoma and spermatocytic seminoma (Table 1). Ba/
F3 cells, normally IL-3 dependent, exhibit proliferation and
survival in the absence of IL-3 when expressing FGFR2 Y376C
[26]. As a congenital mutation, it causes Beare–Stevenson Cutis
Gyrata Syndrome (BSS), a severe craniosynostosis syndrome with a
high risk of infant death due to respiratory complications [27]. In
FGFR3, the introduction of a cysteine residue adjacent to or within
the transmembrane domain, such as G372C, S373C, Y375C, G377C,
I378C or Y381C, also leads to ligand-independent receptor
L.H. Gallo et al. / Cytokine & Growth Factor Reviews 26 (2015) 425–449436activation [28]. Such mutations have been identiﬁed in a variety of
cancers, including bladder cancer, gallbladder cancer, multiple
myeloma, sebborheic keratosis and spermatocytic seminoma
(Table 1). Some of these same mutations have been identiﬁed
congenitally as causing TDI [29].
Other mutations within the transmembrane domain do not
involve the creation of a novel cysteine residue, such as the I379V
mutation in FGFR2 identiﬁed in lung adenocarcinoma (Table 1).
Another example in FGFR3 is G382R that leads to achondroplasia,
the most common rhizomelic dwarﬁsm, originally identiﬁed in the
IIIc isoform as the famous G380R mutation [30,31]. This mutation
leads to abnormal localization of FGFR3 to the plasma membrane,
including a slower rate of internalization and degradation. In
addition, this mutation leads to increased receptor activation [28],
dimerization and MAPK activation [32]. A mutation at the
paralogous site in FGFR2, C383R, has been identiﬁed in endome-
trial carcinoma, esophageal adenocarcinoma and lung squamous
cell carcinomas. Expression of FGFR2 C383R has been shown to
transform NIH3T3 cells [33].
A similar mutation in the transmembrane domain of FGFR4,
G388R, is a common single nucleotide polymorphism (SNP) which
has been examined in many cancers, including bladder, breast,
colon, head and neck, kidney, liver, lung and ovarian cancers, and
neuroblastoma [34]. It is still unclear whether the G388R mutation
is a reliable marker for cancer risk and prognosis. Genomic analysis
of breast epithelial cells revealed that roughly half of the patients
(53%) exhibited a heterozygous FGFR4 G388R variant [35]. Breast
cancer cells expressing FGFR4 G388R exhibit increased motility
and proliferation [36] and acquire resistance to adjuvant therapy
[37]. In contrast, another report found that this SNP is not a
relevant prognostic marker for both node-positive and node-
negative breast cancers [38]. In prostate cancer, cells expressing
FGFR4 G388R display increased proliferation, motility, invasion
and metastasis [39]. In pituitary tumors, the G388R mutation
changes hormone secretion by enhancing growth hormone (GH)
production and leads to S727 phosphorylation of STAT3 that
translocates to the mitochondria and modulates changes in
cellular metabolism [40]. The long term signiﬁcance of this
common polymorphism in human cancer will require further
study.
2.5. Mutations in the kinase domain of FGFRs
The kinase domain of FGFRs is the site of several mutations
with signiﬁcant impact both in human cancer and developmental
syndromes. Of particular importance are mutations within the
activation loop containing the signature motif YYKK and the
major autophosphorylation site, present in all FGFR family
members. First identiﬁed in FGFR3, mutations within this motif
profoundly increase kinase activation, receptor autophosphor-
ylation and downstream signaling [41–43]. These mutations
were initially identiﬁed in the IIIc isoform as K650E or K650M,
with the former causing the neonatal lethal syndrome TDII, and
the latter causing SADDAN (Severe Achondroplasia with Delayed
Development and Acanthosis Nigricans) [29,44,45]. The homolo-
gous mutations K655I and K656D/E/M/N in FGFR1 have been
identiﬁed in pilocytic astrocytoma, glioblastoma and rosette
forming glioneural tumor (Table 1). Similarly, in FGFR2, the
mutations K660E/M/N have been identiﬁed in breast cancer,
cervical squamous cell carcinoma, endometrial carcinoma, lung
squamous cell carcinoma, medulloblastoma, pilocytic astrocyto-
ma and spermatocytic seminoma (Table 1). In FGFR3, the
mutations K652E/M/N/Q/T have been identiﬁed in bladder
cancer, gallbladder cancer, head and neck squamous cell
carcinoma, multiple myeloma, seborrheic keratosis and sperma-
tocytic seminoma (Table 1). Curiously, somatic mutations in theYYKK motif of FGFR4 have not yet been identiﬁed in human
cancer, but this seems only a matter of time.
These activating mutations lead to different processing and
trafﬁcking of the receptors through the secretory pathway [46,47].
For instance, the FGFR3 mutations K652E/M lead to intense
receptor phosphorylation and also defects in glycosylation and
maturation, causing intracellular localization within the endo-
plasmic reticulum (ER). The high level of tyrosine phosphorylation
associated with the receptors in the ER induces activation of STAT1,
STAT3 and STAT5 through the direct recruitment of JAK1 to the ER
and/or Golgi [46]. Nordihydroguaiaretic acid (NDGA), a compound
that inhibits protein trafﬁcking from the ER to Golgi, was found to
inhibit tyrosine phosphorylation of FGFR3 K650E resulting in
impairment of STAT1, STAT3 and MAPK signaling [48].
Although activating mutations in the kinase domain of FGFR3
have been overwhelmingly detected in aggressive cancers, these
mutations are often present in low-grade papillary urothelial
bladder cancers [49,50]. Generation of a mouse model with the
murine equivalent of FGFR3 K652E expressed in the urothelium
did not induce the onset of bladder tumors in mice, but when
combined with deletion of PTEN (a negative regulator of PI3K–
AKT), urothelial tumorigenesis occurred. Combining the activated
FGFR3 with mutations in KRAS or Beta-catenin led to tumor
formation in skin and lung through upregulation of PI3K–AKT
signaling [51]. Thus, in these microenvironmental contexts, it
appears that activating mutations in FGFR3 may synergize with
other mutations that activate PI3K–AKT signaling in these cancers
[52,53].
Another mutation originally identiﬁed as a human develop-
mental syndrome deserves special mention. As a congenital
mutation, the FGFR3 mutation N542K, originally described in
the IIIc isoform as N540K, causes the mild dwarﬁng syndrome
hypochondroplasia [54]. Biochemical studies have shown that this
mutation provides constitutive kinase activation, but much less
than mutations in the YYKK motif [41,55]. This site is located in the
loop between the aC helix and the b4 strand in the kinase hinge
region. This residue participates in a network of hydrogen bonds
that functions as a molecular brake to inhibit FGFR2. This
activating mutation disengages this inhibitory network in the
hinge region and constitutively activates the kinase activity of the
receptor [56]. Somatic mutations at this site commonly occur in
human cancer. In FGFR1, the mutation N546K occurs in
glioblastoma, pilocytic astrocytoma and rosette forming glioneural
tumors. In FGFR2, the mutations N550D/H/K have been identiﬁed
in breast cancer, endometrial carcinoma, gallbladder cancer, head
and neck squamous cell carcinoma and spermatocytic seminoma.
In FGFR3, the mutations N542K/S/T/V have been found in bladder
cancer and spermatocytic seminoma. Lastly, in FGFR4, the
mutations N535D/K have been identiﬁed in rhabdomyosarcoma
(Table 1).
Recently, the importance of the kinase insert (KI) domain in the
functionality of RTK families was described [57]. In comparison
with other RTKs, FGFRs exhibit a short 15-amino acid kinase insert
domain. The KI domain of each FGFR contains possible phospho-
acceptor sites, such as Y583 and Y585 in FGFR1. Interestingly, a
phosphomimic mutation of Y589D has been identiﬁed in the
kinase insert domain of FGFR2 in cervical carcinoma [58]. This
residue is analogous to Y585 in FGFR1, in which phosphorylation of
Y583 and Y585 has been shown to be critical for mitogenesis,
transformation of Ba/F3 cells to IL3-independence and cellular
proliferation [59]. Mutations in this region may provide a
conformational change that increases kinase activation. In FGFR2,
these mutations include P583L in colorectal cancer, G584V/W in
lung adenocarcinoma and lung squamous cell carcinoma, M585V
in cervical squamous cell carcinoma, S588C in breast cancer and
I591M in lung adenocarcinoma. These mutations collectively
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must be involved in the regulation of normal receptor activity and,
when disturbed by mutation, participates in oncogenesis. In
FGFR4, KI domain mutations include G576D in rhabdomyosarcoma
and P583Q in colorectal cancer (Table 1).
2.6. FGFR mutations in cancers of the central nervous system
Pilocytic astrocytoma (PA) is a common central nervous system
neoplasm that accounts for approximately 20% of pediatric tumors
[60] and usually involves alterations within the MAPK pathway;
frequent mutations occur in BRAF such as V600E, or translocations
resulting in a KIAA1549-BRAF fusion protein [61,62]. Genetic
sequencing of non-cerebellar PA tumors identiﬁed mutations in
the kinase domain of FGFR1, including N546K and K656E/M/N [63]
(Table 1). These N546K and K656E mutations have recently been
identiﬁed in rosette-forming glioneuronal tumors (RFNTs), which
are rare cerebellar parenchyma-derived tumors histologically
similar to PA [64]. These mutations, interestingly, have been
found in RFNT occurring in the fourth ventricle, a rare site for PA.
These studies indicate that FGFR1 plays a critical and active role in
the tumorigenesis of a subset of extracerebellar tumors in the
absence of activated BRAF.
Several mutations in each FGFR have been identiﬁed in
glioblastoma. In FGFR1, these mutations include N546K, R576W
and K656E; in FGFR2, Q212K and G463K; in FGFR3, E468K and
R605Q; and in FGFR4, Q144E and R434Q (Table 1) [65]. Except for
the FGFR1 N546K and K656E mutations, analogous to the
hypochondroplasia and TDII mutations in FGFR3, the mode of
action for most of these mutations is not well understood. Of much
greater signiﬁcance in glioblastoma are translocations involving
FGFRs, which will be discussed later.
2.7. FGFR4 activation in rhabdomyosarcoma (RMS)
Activating mutations in FGFR4 have not, so far, been linked to
developmental syndromes. However, it is clear that activating
mutations in FGFR4 play a direct role in the aggressiveness of some
pediatric tumors. Rhabdomyosarcoma (RMS), a soft-tissue sarco-
ma, is a relatively common type of pediatric tumor histologically
divided into two subtypes: embryonal (ERMS) that occurs in the
head, neck and trunk, and alveolar (ARMS) often found in the
extremities [66,67].
Activating mutations in the kinase domain of FGFR4 have been
identiﬁed in approximately 7.5% of primary RMS tumors, including
N535D/K, V550E/L, A554V and G576D mutations (Tables 1 and 2)
[68]. FGFR4 N535K and V550E mutants lead to increased STAT3
activation and drive in vivo pulmonary metastasis in xenograft
models. Dose-dependent inhibition of mutated FGFR4 signaling by
the multi-kinase inhibitor ponatinib leads to ablation of STAT3
signaling resulting in decreased RMS tumor growth in vivo [69].
This small-molecule inhibitor may be a promising candidate toTable 2
Mutations in FGFR4 and PAX-FKHR Fusions in rhabdomyosarcoma.
Mutation Histology PAX-FKHR Pathway activation 
N535D ERMS Absent FGFR4 autophosphorylation;
STAT3 activation; DNA replication
N535K Unknown Absent
V550E ERMS Absent FGFR4 autophosphorylation;
STAT3 activation; DNA replication
V550L ARMS Present
V550L ERMS Absent
A554V ARMS Present
G576D ARMS Presenttreat other cancers harboring these FGFR4 mutations [70].
Additionally, recent genomic sequencing of RMS tumors has
revealed the V550L/M mutations in the kinase domain of FGFR4 in
ERMS tumors (Table 1) [71]. The Val residue at codon 550 is a
gatekeeper residue that controls the accessibility of ATP in the
FGFR catalytic pocket [72].
ARMS is the more severe subtype and 75–80% of ARMS
tumors exhibit a t(2;13) or t(1;13) chromosomal translocation
that generates PAX3-FKHR or PAX7-FKHR fusion proteins,
respectively. FGFR4 is a direct transcriptional target of PAX3-FKHR
in which the enhancer PAX motif is downstream of the FGFR4 gene,
and PAX3-FKHR binding leads to increased expression of FGFR4 in
ARMS. Inhibition of PAX3-FKHR with shRNA leads to reduced
expression in ARMS tumors [73]. PAX3-FKHR-mediated increased
transcription of FGFR4 supports cell survival via the increased
expression of antiapoptotic protein BCL2L1, as shown by shRNA-
mediated suppression of FGFR4 that decreases BCL2L1 expression
[74] (Fig. 3).
The existence of activating mutations in FGFR4, more com-
monly found in ERMS, suggests a similar functional role as fulﬁlled
by the fusion protein PAX-FKHR in ARMS; both pathways result in
increased FGFR4 activation.
2.8. Loss-of-function mutations in FGFR2 in melanoma
Thus far, mutations in FGFRs have been described as resulting
in increased kinase activation. In contrast, all FGFR2 mutations
in melanoma – including mutations located in the kinase
domain – lead to loss-of-function of the receptor (Table 1). Of
particular interest is A649T in FGFR2 detected in a patient
homozygous for this mutation in melanoma [75]. This residue is
located in the FGFR2 activation loop. The introduction of the Thr
side chain hinders the phosphotransfer reaction that is critical
for proper receptor activation, thus resulting in loss-of-function
[76]. Ba/F3 cells expressing FGFR2 A649T exhibit decreased
cellular proliferation compared to wild-type FGFR2, and this
mutation blocks FGF2-induced activation of MAPK signaling.
This mutation was ﬁrst detected as an autosomal dominant
mutation in lacrimo-auriculo-dento-digital (LADD) Syndrome
[77]. These patients exhibit congenital anomalies affecting the
salivary glands, lacrimal glands, teeth and ears. In contrast with
activating mutations in FGFR2 that generally lead to Pfeiffer,
Apert, Crouzon and Beare-Stevenson Syndromes marked by
severe craniosynostosis, LADD patients do not exhibit such
severe phenotypes.
2.9. Stop codon read-through mutations in FGFR3
Thanatophoric Dysplasia (TD) is the most common lethal form
of chondrodysplasia. The K652E activation loop mutation in the
FGFR3 causes TDII, and mutations in the extracellular domains
are usually responsible for TDI. However, TDI can also be causedPhenotype Target drug/outcome Refs.
Pulmonary lesions; pulmonary
Metastases; decreases survival
Ponitinib/Apoptosis [68,69]
Pulmonary lesions; pulmonary
Metastases; decreases survival
Ponitinib/Apoptosis
Fig. 3. FGFR4 signaling contributes to progression of RMS. In ARMS, the PAX-FKHR fusion protein functions as a transcriptional factor to stimulate FGFR4 expression, which
upregulates proliferative and anti-apoptotic pathways. Inhibition of FGFR4 with ponatinib suppresses these effects.
L.H. Gallo et al. / Cytokine & Growth Factor Reviews 26 (2015) 425–449438by unusual mutations at the stop codon of FGFR3, allowing
additional in-frame translation of an additional 423 nt. These
read-through mutations can result in the introduction of a Cys,
Gly or Arg (X809C/G/R). The resulting FGFR3 is 114 amino acids
longer, and the elongated hydrophobic C-terminal region adopts
an a-helix conformation suggested to serve as a second
transmembrane domain that activates FGFR3 [78,79]. Recently,
additional mutations to Leu, Ser, or Trp at the stop codon have
been detected in patients with TDI [80]. Remarkably, in
spermatocytic seminoma, stop codon mutations X809C/G/R/T
in FGFR3 have been observed in 21/29 (72%) of patients [9]
(Table 1). These mutations clearly support cellular proliferation
and clonal expansion of spermatogonia via FGFR3 activation in
these tumors.
2.10. The challenges of drug resistance in tumors with mutated FGFRs
The overall efﬁcacy of tyrosine kinase inhibitors can be limited
due to acquired mechanisms of chemotherapy resistance, which
impedes treatments and leads to tumor relapse [81]. A well-
documented drug resistance mechanism may include the emer-
gence of secondary mutations in gatekeeper residues, such as
T790M in EGFR in 50% of erlotinib- and geﬁtinib-resistant tumors
[82,83] and T315I mutation in BCR-ABL in imatinib-resistant
Chronic Myelogenous Leukemia (CML) [84,85]. Similarly, mutation
of the gatekeeper residue V561M in FGFR1 has been shown to
confer in vitro drug resistance to pyrido-[2,3-d]pyrimidine multi-
kinase inhibitor PP58 [86].
Dovitinib (TKI-258) is an ATP-competitive multikinase
inhibitor with activity against FGFRs [87]. This drug has
shown promising pre-clinical anti-tumor activity in cancers
driven by FGFR activation such as multiple myeloma and acutemyelogenous leukemia [88–90]. In response to dovitinib, FGFR2
mutations were observed including N550H/K/S/T, V565I, E566A/
G and K642N, which resulted in increased receptor kinase
activity. Residues N550, E566 and K642 are part of a triad
that forms a network of autoinhibitory hydrogen bonds termed
the molecular brake. Drug-resistant mutations at these sites
disrupt this molecular brake in the kinase hinge region of FGFR2
[91]. Furthermore, FGFR2 mutations at N550 and K642 have
been identiﬁed in adenoid cystic carcinoma, breast cancer,
endometrial carcinoma, gallbladder cancer, head and neck
squamous cell carcinoma and spermatocytic seminoma
(Table 1) [23,32,92,93].
Furthermore, the use of FGFR inhibitors AZD4547 and AZ8010
for diseases such as multiple myeloma, gastric cancer and
urothelial cancer, has been shown to decrease tumor proliferation
[94]. In order to identify potential mechanisms of resistance to
FGFR inhibitor AZ8010 in multiple myeloma, AZ8010-resistant
multiple myeloma KMS11 cells (KMS11-R) were generated.
KMS11-R cells, which express FGFR3 Y375C, exhibited elevated
levels of phosphorylated FGFR and FRS2, and increased STAT3 and
MAPK signaling [94]. Genomic sequencing of KMS11-R cells
revealed a secondary mutation in the gatekeeper residue V557M
in FGFR3, which is analogous to the V561M mutation in FGFR1 in
PP58-resistant cells. Molecular simulation predicts that the Met
side chain is approximately 25% bulkier than the Val at position
561 in FGFR1, and it restricts the binding of FGFR inhibitor
PD173074 to the catalytic domain [86].
Effective cancer treatments depend upon the prediction of
drug-resistance mechanisms evolved in tumor cells. Without such
predictions, the efﬁcacy of chemotherapy agents is compromised,
contributing to a decrease in treatment progression resulting in
tumor relapse.
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3.1. FGFR fusion protein discovery across a variety of cancers
Fusion proteins are continually being discovered in a variety of
human cancers. Particularly, fusions involving FGFRs are prevalent
in hematological cancers and solid tumors. The existence of
translocations involving FGFRs has been known since the late
1990s, when a patient with T-cell lymphoblastic lymphoma was
found to harbor a ZNF198-FGFR1 fusion, now also referred to as
ZMYM2-FGFR1. Lymphoma or leukemia cases from the 1970s and
1980s described disease characteristics similar to the now well-
deﬁned disease, 8p11 myeloproliferative syndrome (EMS). This
correlation may arise because FGFR1 fusions in leukemia and
lymphoma often originate as EMS. According to the World Health
Organization, EMS is classiﬁed as ‘‘myeloid and lymphoid
neoplasms with FGFR1 abnormalities,’’ and has also been called
‘‘stem cell leukemia/lymphoma’’ [95].
In EMS, FGFR1 located at 8p11.22 is often disrupted by
chromosomal translocation, resulting in a fused coding region.
The fusions in EMS consistently result in FGFR1 fused to an N-
terminal dimerization domain (Fig. 4), an alteration that has also
been found in breast cancer, lung squamous cell carcinoma,
phosphaturic mesenchymal tumor, rhabdomyosarcoma and
leukemia (Table 3) [96–99]. With FGFR as the 30 partner, the
ligand-binding extracellular domain and transmembrane do-
main are excluded from the fusion protein, with only the FGFR
kinase domain attached to the 50 protein partner. Dimerization of
this fusion type would result only from the N-terminal
oligomerization domain, not FGF ligand binding. In solid tumors,
it is more common to ﬁnd FGFR as the 50 fusion gene, with the
breakpoint consistently found in exons 17, 18, or 19, leaving theFig. 4. Structural organization of select FGFR fusion proteins. Schematic representations a
and cell lines. The most common breakpoint of each fusion is shown. Occurrence numb
breakpoints not shown in the ﬁgure. See Table 3 for full list of FGFR fusions and transextracellular, transmembrane and kinase domains intact. When
the extracellular domain is present, dimerization is thought to
increase with the addition of FGF ligand. Although the domains
present in fusion proteins vary, the intact FGFR kinase domain is
always retained, indicating this domain is critical for a
functioning fusion protein and cancer progression. It is rare to
see an FGFR fusion protein with an additional FGFR activating
mutation. The reason may be that either event alone may be
sufﬁcient for cancer to progress, although the dual activation of
an FGFR both by mutation and translocation could provide
additional oncogenic potential. Additionally, while some FGFR
fusions occur with high tissue speciﬁcity, others occur across
many cancer types [100].
3.2. Dimerization of FGFR induced by the fusion partner
In FGFR fusion proteins, almost all fusion partners contribute a
known dimerization domain which allows the FGFR to dimerize
and autophosphorylate the kinase domain, leading to activation
and downstream signaling, increased cell proliferation and cancer
progression (Fig. 1). Recently, an FGFR3 fused to transforming
acidic coiled-coil containing 3 (TACC3) has been discovered in
glioblastoma, bladder cancer, lung cancer, oral cancer, head and
neck squamous cell carcinoma and gallbladder cancer [96,97,101–
107] (Table 3). Additionally, FGFR1-TACC1 has been identiﬁed in
glioblastoma [106,108]. The coiled-coil domain of TACC3 is
assumed to bring the FGFR3 portion of the fusion proteins close
together, inducing activation. FGFR3-TACC3, FGFR3-BAIAP2L1, and
FGFR2-CCDC6 have been shown to dimerize presumably through
their coiled-coil domains [96]. The FGFR2-BICC1 gene fusion has
been found in cholangiocarcinoma, colorectal cancer and hepato-
cellular carcinoma [96,109–111]. The self-associating sterile alphare presented for the more common (n > 5) FGFR fusions identiﬁed in human cancers
ers (n) indicate the total number of times the fusion has been identiﬁed, including
locations.
Table 3
FGFR Fusion Proteins Arising from Translocations.
50 gene Disease FGFR
isoform
50 gene
exon
fusion
point
30 gene 30 gene
exon
fusion
point
Occurrences Translocation Normal biological function/
pathway of FGFR fusion partner
Fusion description Refs.
Fusions with FGFRs as 50 gene
FGFR1 Glioblastoma 17 TACC1 7 2 t(8,8) (p11;p11) Microtubule interaction TK domain: coiled coil domain [106,108]
Pilocytic astrocytoma aA1 18 FGFR1 11 1 duplication Regulation of various cellular
processes
ITD of TK domain [60]
FGFR2 Breast cancer IIIc 19 AFF3 8 1 t(2;10) (q11;q26) Nuclear transcriptional activator TK domain: AFF3 domain [96]
IIIc 19 CASP7 4 1 t(10;10) (q25;q26) Caspase involved in apoptosis,
inﬂammation
TK domain: self association domain [96]
IIIc 19 CCDC6 2 1 t(10;10) (q21;q26) Coiled-coil domain containing
protein
TK domain: coiled coil domain [96]
Cholangiocarcinoma 19 AHCYL1 5 7 t(10;1) (q26.1;p13.2) Adenosylhomocysteinase
activity/IP3 binding
TK domain: coiled coil domain [109]
IIIb 17 BICC1 1 1 t(10;10) (q21.1;q26.1) RNA binding protein TK domain: SAM [111]
17 BICC1 3 1 t(10;10) (q21.1;q26.1) RNA binding protein TK domain: SAM [110]
IIIb 19 BICC1 3 4 t(10;10) (q21.1;q26.1) RNA binding protein TK domain: SAM [96,109]
Not ID’d BICC1 Not ID’d 40 t(10;10) (q21.1;q26.1) RNA binding protein TK domain: SAM [118]
18 KIAA1598/SHOOTIN1 7 1 t(10;10) (q25;q26) Needed for neuronal polarization TK domain: coiled coil domain [110]
IIIb 17 MGEA5 12 1 t(10;10) (q24;q26) O-GlcNAc transferase Unknown [111]
IIIb 19 PPHLN1 4 17 t(10;12) (q26;q12) Epithelial differentiation TK domain: coiled coil domain [118]
IIIb 17 TACC3 11 2 t(4;10) (p16;q26) Stabilization of mitotic spindle TK domain: coiled coil domain [110,111]
Colorectal cancer 19 BICC1 3 1 t(10;10) (q26.1;q21.1) RNA binding protein TK domain: SAM [109]
Hepatocellular
carcinoma
19 BICC1 3 1 t(10;10) (q26.1;q21.1) RNA binding protein TK domain: SAM [109]
Lung adenocarcinoma IIIb 17 CIT 23 1 t(10;12) (q26;q24) Cell division TK domain: coiled coil domain [116]
Lung squamous cell
carcinoma
IIIc 19 KIAA1967/CCAR2 5 1 t(8;10) (p21;q26) Cell cycle and apoptosis
regulator
TK domain: coiled coil domain [96]
IIIc Not ID’d KIAA1967/CCAR2 Not ID’d 1 t(8;10) (p21;q26) Cell cycle and apoptosis
regulator
TK domain: coiled coil domain [98]
Ovarian cancer 17 FAM76A 2 1 t(1;10) (p35;q26) Unknown TK domain: coiled coil domain [117]
Thyroid cancer IIIc 19 OFD1 3 1 t(10;X) (q26;p22) Centriolar component, regulates
Wnt signaling
TK domain: coiled coil; LisH domain [96]
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FGFR3 Bladder cancer IIIb 18 BAIAP2L1 2 2 t(4;7) (p16;q22) Formation of actin TK domain: coiled coil; IMD domain [102,191]
Not ID’d BAIAP2L1 Not ID’d 3 t(4;7) (p16;q22) Formation of actin TK domain: coiled coil; IMD domain [191]
16 TACC3 11 3 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [157]
17 TACC3 4 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [101]
17 TACC3 11 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [101]
IIIb 18 TACC3 4 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [102]
IIIb 18 TACC3 8 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [102]
IIIb/IIIc 18 TACC3 11 5 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [96,102]
Gallbladder cancer 17 TACC3 11 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [107]
Glioblastoma 16 TACC3 8 3 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [106]
16 TACC3 9 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [106]
16 TACC3 10 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [106]
16 TACC3 11 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [106]
17 TACC3 6 2 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108]
17 TACC3 8 5 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108,192]
17 TACC3 10 4 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108,192]
17 TACC3 11 7 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108,192]
18 TACC3 4 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108]
18 TACC3 5 2 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108]
18 TACC3 9 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108]
18 TACC3 10 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [105]
18 TACC3 11 4 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [96,105]
18 TACC3 13 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [108]
IIIc 19 TACC3 4 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [105]
Head and neck
squamous cell
carcinoma
18 TACC3 6 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [193]
IIIb 18 TACC3 10 2 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [96]
18 TACC3 14 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [193]
19 TACC3 11 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [193]
Lung
adenocarcinoma
Not ID’d BAIAP2L1 Not ID’d 1 t(4;7) (p16;q22) Formation of actin TK domain: coiled coil; IMD domain [191]
17 TACC3 4 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [194]
17 TACC3 8 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [194]
17 TACC3 10 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [194]
17 TACC3 11 8 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [97,194]
Lung squamous cell
carcinoma
Not ID’d BAIAP2L1 Not ID’d 1 t(4;7) (p16;q22) Formation of actin TK domain: coiled coil; IMD domain [191]
17 TACC3 5 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [97]
17 TACC3 7 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [103]
17 TACC3 8 2 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [97,103]
17 TACC3 10 2 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [97]
17 TACC3 11 7 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [97,103]
18 TACC3 9 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [103]
18 TACC3 10 2 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [104]
IIIb 18 TACC3 11 6 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [96,97]
Oral cancer IIIb 18 TACC3 10 1 t(4;4) (p16;p16) Stabilization of mitotic spindle TK domain: coiled coil domain [96]
Fusions with FGFRs as 30 gene
BAG4 Lung squamous cell
carcinoma
1 FGFR1 8 2 t(8;8) (p11;p11) Anti-apoptotic protein BAG domain: Ig,TM,TK domains [97]
IIIc 2 FGFR1 9 1 t(8;8) (p11;p11) Anti-apoptotic protein BAG domain: Ig,TM,TK domains [96]
Not ID’d FGFR1 Not ID’d 3 t(8;8) (p11;p11) Anti-apoptotic protein BAG domain: Ig,TM,TK domains [98]
ERLIN2 Breast cancer IIIc 10 FGFR1 4 1 t(8;8) (p11;p11) Lipid raft associated protein
family
SPFH domain: Ig, TM, TK domain [96]
FN1 Phosphaturic
mesenchymal
tumor
22 FGFR1 3,4 1 t(2;8) (q35;p11) Cell adhesion FN domain: Ig, TM, TK domain [137]
23 FGFR1 3,4 1 t(2;8) (q35;p11) Cell adhesion FN domain: Ig, TM, TK domain [137]
28 FGFR1 5 1 t(2;8) (q35;p11) Cell adhesion FN domain: Ig, TM, TK domain [137]
Not ID’d FGFR1 Not ID’d 6 t(2;8) (q35;p11) Cell adhesion FN domain: Ig, TM, TK domain [137]
FOXO1 Rhabdomyosarcoma Not ID’d FGFR1 Not ID’d 1 t(8;13;9) (p11.2;q14;
q32)
Transcription factor Unknown [136]
SQSTM1 Leukemia 9 FGFR1 9 1 t(5;8) (q35;p11) Ubiquitin binding, NFkB
regulation
PB1-ZF: TK domain [138]
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Table 3 (Continued )
50 gene Disease FGFR
isoform
50 gene
exon
fusion
point
30 gene 30 gene
exon
fusion
point
Occurrences Translocation Normal biological function/
pathway of FGFR fusion partner
Fusion description Refs.
TEL/ETV6 Lymphoma 5 FGFR3 10 1 t(4;12) (p16;p13) ETS family of transcription
regulators
SAM: TK domain [99,195]
8p11 myeloproliferative syndrome (EMS) resulting from fusions of FGFR1
BCR 8p11
myeloproliferative
syndrome (EMS)
4 FGFR1 9 10 t(8;22) (p11;q11) Serine/Threonine kinase Coiled coil domain: TK domain [95,196–201]
Not ID’d FGFR1 Not ID’d 5 t(8;22) (p11;q11) Serine/Threonine kinase Coiled coil domain: TK domain [95,113,202,
203]
CEP110/
centriolin
Not ID’d FGFR1 8 2 t(8;9) (p11;q33) Required for centrosome
function
LZ/coiled coil domain: TK domain [123,204]
38(15)(40) FGFR1 9 4 t(8;9) (p11;q33) Required for centrosome
function
LZ/coiled coil domain: TK domain [95]
Not ID’d FGFR1 Not ID’d 7 t(8;9) (p11;q33) Required for centrosome
function
LZ/coiled coil domain: TK domain [95]
CPSF6 8 FGFR1 9 1 t(8;12) (p11;q15) RNA processing RNA recognition motif: TK domain [95]
Not ID’d FGFR1 Not ID’d 2 t(8;12) (p11;q15)/
dic(8;12) (p11;p11)
RNA processing RNA recognition motif: TK domain [95]
CUX1 11 FGFR1 10 1 t(7;8) (q22;p11) Homeodomain family of DNA
binding proteins
Coiled coil domain: TK domain [114]
FGFR1OP
(FOP)
5 FGFR1 9 1 t(6;8) (q27;p11-12) Microtubule anchoring Leu rich domain: TK domain [95]
6 FGFR1 9 4 t(6;8) (q27;p11-12) Microtubule anchoring Leu rich domain: TK domain [95]
7 FGFR1 9 2 t(6;8) (q27;p11-12) Microtubule anchoring Leu rich domain: TK domain [95]
Not ID’d FGFR1 Not ID’d 3 t(6;8) (q27;p11-12) Microtubule anchoring Leu rich domain: TK domain [95]
FGFR1OP2 4 FGFR1 9 3 t(8;12) (p11;p12)/
ins(12;8) (p11;p11p22)
Wound healing Coiled coil domain: TK domain [95,115,205]
HERV-K 3 FGFR1 9 1 t(8;19) (p12; q13.3) Retroviral sequence LTR: TK domain [206]
Not ID’d FGFR1 Not ID’d 1 t(8;19) (p12; q13.3) Retroviral sequence LTR: TK domain [139]
LRRFIP1 9 FGFR1 9 1 t(2;8) (q37;p11) Transcriptional repressor Coiled coil domain: TK domain [95]
MYO18A 32 FGFR1 9 1 t(8;17) (p11;q23) Golgi membrane trafﬁcking and
shape
Coiled coil domain: TK domain [95]
NUP98 Not ID’d FGFR1 Not ID’d 1 t(8;11) (p11;p15) Nuclear pore complex
component
Unknown [95]
RANBP2/
NUP358
20 FGFR1 9 1 t(2;8) (q12;p11) Nuclear pore complex
component
LZ: TK domain [128]
TRIM24
(TIF1)
12 FGFR1 9 1 t(7;8) (q34;p11) Transcription control Coiled coil domain: TK domain [95]
TPR 22 FGFR1 13 1 t(1;8) (q25;p11.2) Nuclear pore complex
component
Coiled coil domain: TK domain [207]
23 FGFR1 13 1 t(1;8) (q25;p11.2) Nuclear pore complex
component
Coiled coil domain: TK domain [119]
Not ID’d FGFR1 Not ID’d 1 t(1;8) (q25;p11.2) Nuclear pore complex
component
Coiled coil domain: TK domain [208]
ZNF198/
ZMYM2
17 FGFR1 9 34 t(8;13) (p11;q12) Transcription factor ZF: TK domain [95,209]
Note: Several fusions are described in an earlier review article, Ref [95].
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domain, fused 30 to FGFR2, is believed to instigate constitutive
dimerization of FGFR2 in order to produce an active receptor [100]
(Fig. 4).
Other dimerization domains found in FGFR fusion proteins are
believed to have the same function. FGFR fusion partner domains
include zinc-ﬁnger, leucine zipper, coiled-coil, SAM, LIS1-homolo-
gous (LIsH), IRSp53/MIM (IMD), BAG, FN1, AFF3, and stomatin/
prohibitin/ﬂotillin/HﬂK/C (SPFH) domains (also known as the
prohibitin PHB domain) (Table 3). Other fusions thought to dimerize
by self-association domain include FGFR2-CASP7 in breast cancer,
which dimerizes through active site loops, and CPSF6-FGFR1, which
dimerizes through a RNA recognition motif [95,96,112]. The most
frequent fusion partner domain is the coiled-coil, occurring in the
proteins mentioned above; in addition, the other coiled-coil fusion
proteins are BCR-FGFR1 [113], CEP110-FGFR1 [95], CUX1-FGFR1
[114], FGFR1OP2-FGFR1 [115], FGFR2-AHCYL1 [109], FGFR2-CIT
[116], FGFR2-FAM76A [117], FGFR2-KIAA1598 [110], FGFR2-
KIAA1967 [96], FGFR2-OFD1 [96], FGFR2-PPHLN1 [118], FGFR2-
TACC3 [111], LRRFIP1-FGFR1 [95], MYO18A-FGFR1 [95], TRIM24-
FGFR1 [95], and TPR-FGFR1 [119].
In order for autophosphorylation to occur, RTKs need to be
exactly aligned. It has been shown that dimerization of the
intracellular domain alone will not activate the receptor. Ligand
binding rotates and aligns the extracellular juxtamembrane
domain and intramembrane a-helices, leading to intracellular
kinase domain alignment, dimerization and activation [24]. To
create an active FGFR fusion protein, the dimerization domain
must provide the correct alignment. The most common FGFR1
fusion in EMS is ZNF198-FGFR1, which contains either 4 or 10 zinc
ﬁnger domains and a proline-rich domain from ZNF198, followed
by the tyrosine kinase domain of FGFR1 (Fig. 4) [95]. The proline-
rich domain is a self association domain and is essential for
dimerization and activation of FGFR1 [120].
An exception to the activation-by-oligomerization theme is an
internal tandem duplication (ITD) of FGFR1 in a patient with
pilocytic astrocytoma [60], resulting in a duplication of the FGFR1
kinase domain. ITD has previously been observed in Acute Myeloid
Leukemia with FLT3, another receptor tyrosine kinase. This ITD,
which occurs in the juxtamembrane domain of FLT3, leads to
enhanced receptor activation and increased downstream signaling
of MAPK and STAT5 [121].
3.3. Altered cellular localization of FGFR by the fusion partner
Often, the creation of FGFR fusion proteins not only activates
FGFR and its canonical pathways, but results in an incongruous
FGFR localization as well. Some partner proteins can lead to
localization of FGFR to a cellular compartment other than the
plasma membrane. Fusion proteins that have been shown to have
irregular localization include FGFR1OP-FGFR1, CEP110-FGFR1,
ZNF198-FGFR1, and TEL-FGFR3 in lymphoma and FGFR3-TACC3
in glioblastoma. Wild-type FGFR1OP (FGFR1 oncogenic partner)
and CEP110 (centriolin) are centrosomal proteins. Once engaged in
a fusion with FGFR1, FGFR1OP localizes the kinase domain to the
centrosome through a CAP350 interaction [122]. CEP110 is
involved in centriole maturation and localizes to the centrosome
via an 170-amino acid region in the C-terminus, a region retained
in the CEP110-FGFR1 fusion. Instead of the expected localization to
the centrosome, cytoplasmic expression of the fusion protein was
observed [123]. Continuous kinase activity and inappropriate
cytoplasmic localization due to CEP110-FGFR1 fusion formation
may result in increased cell viability and hematopoietic stem cell
growth. The fusion proteins ZNF198-FGFR1 and TEL-FGFR1 have
been identiﬁed as cytoplasmic proteins [95,99]. The translocation
of ZNF198 and FGFR1 genes removes the FGFR1 transmembranedomain and the C-terminal nuclear localization signal of ZNF198,
which most likely leads to cytoplasmic localization.
Expressed FGFR3-TACC3 has been shown to localize to the
mitotic spindle poles in dividing mouse astrocytes, most likely due
to recruiting effects of TACC3. In addition, the fusion protein
increased the percentage of aneuploidy by greater than 2.5-fold
[106]. As TACC3 is an important component of mitotic spindle
assembly and is involved with the attachment of chromosomes to
microtubules, it is most likely playing a role in chromosomal
segregation errors. During mitosis, wild-type TACC3 is strongly
diffused around centrosomes, due to the localizing effects of the C-
terminal coiled-coil [124]. As this domain is present in the FGFR3
fusion, multiple effects could be implicated by the fusion protein
such as localization of FGFR3-TACC3 to the centrosome or a novel
biochemical activity. During interphase, wild-type TACC3 has been
found to be concentrated in the nucleus [124]. The location of the
FGFR3-TACC3 fusion in non-dividing cells has not yet been
identiﬁed.
Although the localization of ERLIN2-FGFR1 has not yet been
investigated, wild-type ERLIN2 anchors to the ER membrane via
an N-terminal binding motif. This motif is still present when
ERLIN2 is fused to FGFR1, and may be affecting fusion protein
location [125]. The fusion results in the SPFH oligomerization
domain of ERLIN2 fused 50 to exon 4 of FGFR1, and was detected in
breast cancer.
Thus, for these and other FGFR fusion proteins discussed: is the
salient biological feature the localization of the FGFR kinase
domain to a novel cellular compartment? Or, is it the constitutive
dimerization and activation of the FGFR kinase domain, regardless
of the localization of the normal fusion partner, that is
determinative? Much further experimental research will be
required to arrive at a deﬁnitive answer.
3.4. Downstream signaling impacts of fusion proteins
FGFR fusion proteins have been shown to activate the normal
FGFR pathways, speciﬁcally the PI3K/AKT, MAPK, and JAK/STAT
pathways (Fig. 1). FGFR3-TACC3, FGFR3-BAIAP2L1, and FGFR2-
CCDC6 increase activation of PI3K/AKT and MAPK pathways [100].
FGFR2-TACC3 has also been shown to increase MAPK activation,
but only a moderate increase of FRS2 phosphorylation of the PI3K
pathway has been seen [111]. In wild-type FGFR1, FRS2 normally
binds to the juxtamembrane domain between amino acids 407 and
433. In many FGFR1 fusions, this domain is either fully or partially
disrupted by translocation of the fusion partner, which results in
an inability to recruit FRS2. This has been shown to occur in
ZNF198-FGFR1, but may occur in other fusion proteins with FGFR
as the 30 partner. However, although FRS2 interaction with
ZNF198-FGFR1 was undetectable, the PI3K pathway remained
active [95].
In addition to the activation of MAPK and PI3K pathways, cells
expressing FGFR1OP-FGFR1 exhibit increased phosphorylation of
STAT1 and STAT3, but not STAT5 [126]. Furthermore, ZNF198-
FGFR1 activates STAT5, FGFR3-TACC3 activates STAT3, and FGFR3-
BAIAP2L1 and FGFR2-CCDC6 increase STAT1 activation [100,122].
ERLIN2-FGFR1 and CEP110-FGFR1 have been shown to be
biologically active through tyrosine phosphorylation of the
respective fusion proteins, but further downstream signaling
activation has not been explored [96,123]. Despite an overall
increase in cell proliferation pathway activation, a contrasting
study reports a failure to over-activate MAPK and AKT by FGFR3-
TACC3 [106]. Studies exploring FGFR2-AHCYL1 and FGFR2-BICC1
fusions report an absence of AKT and STAT3 phosphorylation,
although the MAPK pathway remained active [109]. Additionally,
TEL-FGFR3 directly interacts with and activates STAT3 and STAT5,
presumably through the FGFR3 portion of the protein, an
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[99].
Fusions with FGFR as the 50 partner usually result in a deletion
of the last exon of FGFR, which includes the tyrosine residue
important for PLCg binding [127]. In bladder cancer, cells
transfected with FGFR3-TACC3 or FGFR3-BAIAP2L1 were unable
to activate PLCg, due to a deletion of the last exon of FGFR3 in both
fusion proteins [102] (Fig. 4) Chromosomal rearrangements such
as these also result in the loss of the 30 UTR (untranslated region) of
FGFR, signiﬁcant as a region that contains various microRNA
(miRNA) regulation sites. MiR-99a is normally present at high
levels in the brain and results in a downregulation of FGFR3
translation. The formation of FGFR3-TACC3 fusion in glioblastoma
results in a loss of the miR-99a site, which leads to the
overexpression of FGFR3-TACC3. This miRNA site is unique to
FGFR3, but overexpression due to a loss of miRNA regulation could
occur in any FGFR fusion where the 30 UTR region contains a
regulatory miRNA site [105].
Interestingly, nuclear pore complex proteins have been
identiﬁed in fusion proteins with FGFR1. RANBP2-FGFR1, TPR-
FGFR1, and NUP98-FGFR1 have all been identiﬁed in EMS
[95,119,128]. Mechanistically, these may be similar to other fusion
proteins discussed previously in that two of these possess
dimerization domains, with RANBP2 (RAN binding protein 2, also
NUP358) containing a leucine zipper domain and TPR (Translo-
cated Promoter Region) containing a coiled-coil domain (Table 3).
A dimerization motif in NUP98 has not yet been identiﬁed,
however. Also mechanistically unclear is the fusion partner AFF3
(AF4/FMR2 Family, Member 3, also known as LAF4), a nuclear
transcriptional activator, which has been identiﬁed as the 30 fusion
partner with FGFR2 (Table 3). AFF3 has also been found fused to the
MLL gene in acute lymphoblastic leukemia [129]. It is unclear
whether the signiﬁcant biochemical consequence of these fusion
proteins is manifested in the dimerization and activation of the
FGFR partner, or whether the abnormal nuclear localization of the
FGFR component represents the key event.
All EMS cases with FGFR1 fusions have thus far been negative
for the BCR-ABL fusion gene, which occurs in 85–90% of CML. The
remaining cases either contain other translocations or are
classiﬁed as BCR-ABL negative CML, or atypical CML. Some of
these atypical CML cases are now linked to the broad spectrum of
EMS cases, due to the presence of a translocation involving the
8p11 region [130]. Patients with BCR-FGFR1 [t(8;22)(p11;q11)]
fusion are often referred to as CML-like due to their greater
resemblance to CML than to EMS. BCR has been shown to interact
with Grb2 by phosphorylation of Y177 [95]. This interaction is
thought to be important for BCR-ABL signaling in CML patients, and
may be playing a role in EMS patients with BCR-FGFR1 as well.
3.5. Inhibition of FGFR fusion proteins
Through the use of various drug treatments, a reduction of cell
proliferation and FGFR fusion protein activity has been accom-
plished. Studies indicate that an active FGFR kinase domain drives
cancer progression, thus the goal of many cancer treatments is to
inhibit the FGFR portion of the fusion [106,109]. FGFR inhibitors
have been used in vitro to reduce phosphorylation of FGFR and
subsequent downstream signaling proteins. FGFR kinase inhibi-
tors AZD4547, BGJ398, and PD173074 have inhibited growth of
FGFR3-TACC3-expressing Rat1A and glioma stem-like cells (GSC-
1123). PD173074 and AZD4547 both resulted in tumor shrinkage
during in vivo mouse xenograft studies as well [106]. For fusions
FGFR2-AHCYL1 and FGFR2-BHCC1, both BGJ398 and PD173074
were successful in reducing in vitro fusion activity and cell growth
[109]. In bladder cancer, sensitivity of FGFR3-TACC3 and FGFR3-
BAIAP2L1 to the kinase inhibitors PD173074, dovitinib, SU5402,and BGJ398 has been reported [102]. BGJ398 and dovitinib are
currently involved in numerous clinical trials (clinicaltrials.gov).
FGFR3 translocations were also targeted using the heat shock
protein 90 (HSP90) inhibitor, ganetespib (STA-9090). By
inhibiting HSP90, hundreds of proteins soon become degraded,
which disrupts oncogenic signaling pathways. Ganetespib
treatment of bladder cancer cell line RT112, which contains
FGFR3-TACC3, resulted in a decrease of fusion protein expres-
sion and cell viability. Expression of the apoptosis facilitator
protein BIM (BCL2-Like 11, or BLC2L11) was induced, indicative
of apoptotic pathway activation. Combination of ganetespib
with BGJ398 proved to be the most effective in causing cell death.
However, ganetespib had differential effects on protein expres-
sion and cell viability in RT4 and SW780 cell lines, which contain
FGFR3-TACC3 and FGFR3-BAI1AP2L1, respectively. While HSP90
inhibitors 17-AAG and 17-DMAG reduced cell viability, resis-
tance to ganetespib was exhibited. This discrepancy may be due
to differences in drug movement or metabolism [131]. Other
HSP90 inhibitory compounds were effective in killing cells
expressing BCR-ABL in vitro [122]. These results collectively
indicate the potential of HSP90 inhibitors against fusion positive
cases.
In cholangiocarcinoma, pazopanib (GW786034B) followed by
ponatinib (AP24534) treatment, both RTK inhibitors, induced anti-
tumor activity in a patient with FGFR2-TACC3. Ponatinib treatment
also led to anti-tumor activity in a patient exhibiting FGFR2-
MGEA5 fusion. Ponatinib has been FDA approved for treatment of
the drug resistant T315I mutation in BCR-ABL fusion protein in
CML [111].
In EMS, the small number of patients who have achieved long
term remission have received hematopoietic stem cell transplan-
tation. Many therapies used for acute lymphoblastic leukemia,
acute myeloid leukemia, and myeloproliferative neoplasms have
proven unsuccessful or display only short term remission against
EMS. FGFR1 kinase inhibitor SU5402 has shown promise,
demonstrating inhibitory effects in cells expressing BCR-FGFR1
or ZNF198-FGFR1. Interestingly, PI3K, farnesyltransferase, and p38
inhibitors were also successful in reducing growth of these cells,
whereas MEK inhibitor PD98059 was not [130]. This is distinct
from the MEK inhibitor U0126, which was shown to inhibit growth
of cells expressing FGFR3-TACC3 [105]. While dovitinib has been
successful in inhibiting the proliferation of Ba/F3 cells transfected
with ZNF198-FGFR1 or BCR-FGFR1 and cell lines expressing
FGFR1OP2-FGFR1, a push for effective FGFR1 inhibitors is needed
for EMS cases [132].
3.6. Translocations leading to FGFR overexpression without creation
of a fusion protein
Some translocations do not create a novel fusion protein;
rather, these result in overexpression of FGFR. In the translocations
of SLC45A3-FGFR2 in prostate cancer and IgH-MMSET-FGFR3 in
Multiple myeloma (MM), the partner gene promoter now controls
FGFR transcription, which alters the expression levels of the
receptor. SLC45A3-FGFR2 translocation results in the endogenous
promoter and exon 1 noncoding region of SLC45A3 attached 50 to
the FGFR2 gene, which places FGFR2 transcription under the
control of an androgen-regulated promoter. This leads to FGFR2
overexpression and oncogenicity [96].
Multiple myeloma (MM) is characterized by a growth of
malignant cells in the bone marrow. In approximately 20% of MM
cases, a t(4;14) (p16.3;q32) translocation places MMSET and
FGFR3 under the control of the IgH promoter, leading to
overexpression of FGFR3 [133]. The overexpressed FGFR3 often
contains an additional mutation, resulting in functional changes
such as resistance to tyrosine kinase inhibitors (V557M),
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tion (K652E) [94]. However, one third of cases with this
translocation lose FGFR3 expression while IgH is overexpressed.
Additionally, although rare, translocations between FGFR3 and an
immunoglobulin gene enhancer have been found in chronic
lymphocytic leukemia (CLL), including t(4;14) (p16;q32) between
FGFR3 and IgH, and t(4;22) (p16;q11.2) involving FGFR3 and IgL
[134,135].
MM cases with the t(4;14) translocation have shown partial
responsiveness to the FGFR3 inhibitor PD173074 and RTK inhibitor
sunitinib (SU-11248). During in vitro studies, both inhibitors halted
cell growth and inhibited FGFR3 activity, inducing an apoptotic
response. However, during in vivo studies, tumor growth in the
translocation-positive model was not inhibited by sunitinib, even
though sunitinib was active in the translocation-negative tumors.
The difference between the in vitro and in vivo data may be due to a
difference in tumor microenvironment [133]. These studies also
revealed that RTK inhibitors PD173074, sunitinib, and vandetanib
(ZD6474) inhibited viability of Ba/F3 cells transformed with
ZNF198-FGFR1. Sunitinib, which inhibits many RTKs, is approved
for metastatic renal cell carcinoma treatment [133], and is being
examined in clinical trials for relapsed multiple myeloma patients.
Additionally, masitinib (AB1010, a TK inhibitor) has entered phase
II clinical trials for MM patients with the t(4;14) translocation
[clinicaltrials.gov].
3.7. Genomic events that contribute to FGFR fusion proteins
Although the occurrence of FGFR fusion proteins may be rare,
there are similarities between fusions. Fusions with FGFR as the 50
partner have only been found in solid tumors so far. In contrast,
fusions with FGFR as the 30 partner have consistently been found in
EMS, which predisposes patients to either lymphoma, leukemia, or
both. A few exceptions have been ERLIN2-FGFR1 found in breast
cancer [96], BAG4-FGFR1 in lung squamous cell carcinoma (LUSC)
[96], FOXO1-FGFR1 in rhabdomyosarcoma [136], TEL-FGFR3 in
lymphoma [99], FN1-FGFR1 in phosphaturic mesenchymal tumor
[137], and SQSTM1-FGFR1 in leukemia [138] (Table 3).
While the mechanism and cause of gene rearrangements is
unknown, both intrachromosomal and interchromosomal rear-
rangements have been identiﬁed. Rearrangements in the form of
tandem duplication, inversion, deletion, or translocation have all
been identiﬁed as FGFR fusion formation events. Translocations
occur when two double stranded breaks on different chromosomes
rearrange and repair [100]. Fusion genes joined by a translocation
can result in the formation of a reciprocal gene (i.e. FGFR2-BICC1
and BICC1-FGFR2 genes). This has been reported in some cases,
such as BCR-FGFR1, CEP110-FGFR1, FGFR1OP-FGFR1, FGFR2-
AHCYL1, FGFR2-BICC1, HERVK-FGFR1, LRRFIP1-FGFR1, RANBP2-
FGFR1, SQSTM1-FGFR1, TIF1-FGFR1, and ZNF198-FGFR1 fusions
[95,109–111,123,128,138,139]. However, reciprocal transloca-
tions have not been shown to be translated into functional
proteins. The majority of these studies do not report the presence
of a reciprocal fusion gene, and this may be indicative of another
genetic alteration, such as an insertion or complex rearrangement,
which would preclude the formation of the reciprocal gene [95].
The formation of these chromosomal rearrangements may
occur due to common chromosomal fragile sites (CFSs). An
increasing number of studies have identiﬁed CFSs as areas
commonly affected by deletions, ampliﬁcations, and rearrange-
ments in cancer [140]. CFSs have become linked to genomic
instability, the driving force of cancer. Chromosomal breakpoints
identiﬁed in cancer match to 67% of fragile sites induced in vitro
[140]. All individuals posses CFSs, and these regions have been
identiﬁed as evolutionarily conserved. CFSs contain tandem repeat
sequences, often ﬂexible AT-rich repeats and the formation ofnon-B-DNA secondary structures. Additionally, the fragile nature
of CFSs has been linked to a lack of replicating origins within the
CFS region, which may lead to incomplete replication. CFS
expression is also speciﬁc to tissue or cell type. An investigation
should be made into the correlation between CFS and tumor-
speciﬁc gene rearrangements, as seen with some FGFR fusion
protein expression. Mutagens and carcinogens often target CFS
regions. Regulation of CFS occurs by DNA damage response
proteins, including the ataxia telangiectasia mutated (ATM)
pathway. This pathway is downregulated in cholangiocarcinoma
patients with FGFR2 fusions [118].
CFS FRA10F has been identiﬁed at 10q26, a region which
contains the FGFR2 gene [111], though some indicate FGFR2 is
proximal to FRA10F [140]. FGFR2 is also surrounded by ribosomal
protein pseudogenes (RPS15AP5 and RPL19P16), which contain
repetitive bases, leading to genomic instability [111]. Although not
thoroughly investigated, these factors could be an indication of the
high level of genomic rearrangements seen in the FGFR2 region. In
this regard, it may be noteworthy that 10 of 107 cholangiocarci-
noma patients simultaneously exhibited two different fusions,
FGFR2-BICC1 and FGFR2-PPHLN1 [118]. CFS regions have also been
identiﬁed on the X chromosome, in regions ﬂanking the ODF1 gene,
which has been identiﬁed in a FGFR2-ODF1 fusion in thyroid
cancer [96,140]. As seen (Table 3), FGFR1, FGFR2, and FGFR3
rearrangements predominate while, for unknown reasons, FGFR4
fusions are strikingly absent.
4. Concluding remarks
Aberrant FGFR signaling, either due to activating mutations or
the presence of fusion proteins, supports cellular proliferation,
tumorigenesis, and cancer progression. Although extensive re-
search has shown that targeting FGFRs with small molecule
inhibitors halts receptor activation, downstream signaling and
results in tumor shrinkage, secondary mutations that contribute to
drug resistance in tumors are challenges to successful clinical
treatment. In addition, FGFRs fused to dimerizing partners brings a
new level of complexity in terms of receptor activation and the
speciﬁcity of small-molecule inhibitors. The development of FGFR
therapeutics with personalized speciﬁcity will advance treatments
of patients whose tumors harbor activated FGFRs via mutation or
fusion protein.
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